Vyome Holdings, Inc.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Venkateswarlu Nelabhotla
- Full Time Employees
- 18
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 100, Overlook Center Princeton NJ United States of America 08540
- IPO Date
- Oct 6, 2016
- CIK
- 0001427570
- Website
- vyometx.com
- Similar Companies
- Business
- Vyome Holdings, Inc. Vyome Holdings, Inc. (Nasdaq: HIND) is a clinical-stage biotechnology company that develops therapeutic products targeting immuno-inflammatory and rare diseases, including topical formulations such as VT-1953 for malignant fungating wounds, VT-1908 for uveitis, and VB-1953 for drug-resistant acne vulgaris; the company also pursues opportunities in medical devices and AI-driven healthcare solutions across its three-pillar platform synergizing biotech, devices, and artificial intelligence. Headquartered in Cambridge, Massachusetts, with operations spanning the US-India innovation corridor through subsidiaries Vyome Therapeutics, Inc. and Vyome Therapeutics Limited in Delhi, India, Vyome Holdings was founded in 2017 and serves patients with underserved conditions in global markets. In August 2025, the company completed a reverse merger with ReShape Lifesciences Inc., began trading on Nasdaq under the HIND ticker, announced positive interim Phase 2 data for VT-1953 showing malodor reduction in malignant fungating wounds, initiated a strategic review of its Livechain Inc. subsidiary, and signed a memorandum of understanding with Embryyo Technologies to develop AI-enabled medical devices in oncology, surgery, and wearables.
Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet
Vyome Holdings Reports First Quarter 2026 Results With Key FDA Filings and Strong Balance Sheet
Vyome Strikes Deal With Impetis Biosciences, Opening A ~$57B Market Opportunity
Vyome Presents Transformational VT-1953 Phase 2 Clinical Study Data at Prestigious AACR 2026
Vyome to Present Compelling Phase 2 Clinical Data on VT-1953 for Treatment of MFW at AACR 2026
Vyome Reports Transformational 2025 Results: Company Well Positioned for Breakout Phase
Vyome Announces the Publication of Positive Preclinical Results in Uveitis, Addressing a $3B Potential Market Opportunity
Vyome Files for VT-1953 Orphan Drug Status, Furthers Strategic Focus On VT-1953 Program Over the Next 6 Months
Vyome Successfully Capitalizes All VT-1953 Funding Requirements For Initial Phase 3 Results
Independent Analyst Values Vyome's VT-1953 at USD 1 Billion Upon Successful Completion of Phase 3 Study
Vyome (NASDAQ:HIND) versus Medline (NASDAQ:MDLN) Critical Review
Vyome (NASDAQ:HIND) & Medline (NASDAQ:MDLN) Critical Analysis
Vyome Subsidiary LiveChain (LICH) to Acquire Senior Secured Note in Humanyze, An MIT Incubated Company
Analyzing Profusa (NASDAQ:PFSA) & Vyome (NASDAQ:HIND)
Critical Survey: Perspective Therapeutics (NASDAQ:CATX) & Vyome (NASDAQ:HIND)
Vyome Reports Positive Final Phase 2 Results for VT-1953; Plans to Advance Into Pivotal Study For FDA Approval
Profusa (NASDAQ:PFSA) versus Vyome (NASDAQ:HIND) Head to Head Analysis
Vyome Appoints Renowned Medical Oncologist, Dr. Aditya Bardia, as Senior Medical Advisor to Guide the Development of MFW Program
Vyome Holdings Announces Transformational First Quarter Following Nasdaq Listing
Vyome Holdings Announces Results of Annual Shareholder Meeting